secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125329
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Q3 net loss $23.2M; cash $84.7M; Revita studies on track
-----------------------------------------------------------------------

- Net loss $23.2M vs $15.7M YoY; R&D expense $19.0M (up from $9.4M) on clinical progress.
- Cash and equivalents $84.7M; expected to fund operations into Q4 2025.
- REMAIN-1 mid-point analysis expected Q2 2025; REVEAL-1 open-label data start Q4 2024.
- REVITALIZE-1 topline data expected mid-2025; RJVA-001 CTA submission by YE 2024.
- Nominated RJVA-002, first smart GIP/GLP-1 pancreatic gene therapy candidate for obesity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/0000950170-24-125329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/guts-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer